» Articles » PMID: 26804898

Characteristics of Veterans Receiving Buprenorphine Vs. Methadone for Opioid Use Disorder Nationally in the Veterans Health Administration

Overview
Publisher Elsevier
Specialty Psychiatry
Date 2016 Jan 26
PMID 26804898
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The advent of buprenorphine as an alternative to methadone has dramatically shifted the landscape of opioid agonist therapy (OAT) for opioid use disorder (OUD). However, there is limited US national level data describing thedifferences between patients who are prescribed these two OAT options.

Methods: From veterans with OUD diagnosis who used Veterans Health Administration services in 2012, we identified 3 mutually exclusive groups: those who received (1) buprenorphine only (n=5,670); (2) methadone only (n=6,252); or (3) both buprenorphine and methadone in the same year (n=2513). We calculated the bi-varate effect size differences (risk ratios and Cohen's d) forcharacteristics that differentiated these groups. Logistic regression analysis was then used to identify factors independently differentiating the groups.

Results: Ten year increment in age (OR 0.67; 95% CI 0.64-0.70), urban residence (OR 0.26; 95% CI 0.25-0.33), and black race (OR 0.39; 95% CI 0.35-0.43) were strongly and negatively associated with odds of receiving buprenorphine compared to methadone, while medical and psychiatric comorbidities or receipt of other psychiatric medications did not demonstrate substantial differences between groups.

Conclusions: Differences between veterans receiving buprenorphine or methadone based OAT seems to be largely shaped by demographic characteristics rather than medical or psychiatric or service use characteristics. A clearer understanding of the reasons for racial differences could be helpful in assuring that black OUD patients are not denied the opportunity to receive buprenorphine if that is their preference.

Citing Articles

Pain, Substance Use Disorders, Mental Health, and Buprenorphine Treatment among Patients With and Without HIV.

Miller E, McGinnis K, Edelman E, Feinberg T, Gordon K, Kerns R AIDS Behav. 2024; 28(12):3994-4004.

PMID: 39264485 PMC: 11586311. DOI: 10.1007/s10461-024-04494-w.


Patients' Perspectives on Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder.

Wyse J, Eckhardt A, Waller D, Gordon A, Shull S, Lovejoy T J Addict Med. 2024; 18(3):300-305.

PMID: 38498620 PMC: 11853618. DOI: 10.1097/ADM.0000000000001292.


Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries.

Miles J, Treitler P, Hermida R, Nyaku A, Simon K, Gupta S Drug Alcohol Depend. 2023; 252:110963.

PMID: 37748421 PMC: 10615876. DOI: 10.1016/j.drugalcdep.2023.110963.


Trajectories of drug treatment and illicit opioid use in the AIDS Linked to the IntraVenous Experience cohort, 2014-2019.

Rudolph J, Cepeda J, Astemborski J, Kirk G, Mehta S, Genberg B Int J Drug Policy. 2023; 118:104120.

PMID: 37429162 PMC: 10528295. DOI: 10.1016/j.drugpo.2023.104120.


Weight change among patients engaged in medication treatment for opioid use disorder: a scoping review.

Carr M, Lou R, Macdonald-Gagnon G, Peltier M, Funaro M, Martino S Am J Drug Alcohol Abuse. 2023; 49(5):551-565.

PMID: 37200510 PMC: 10840392. DOI: 10.1080/00952990.2023.2207720.


References
1.
Gamache G, Rosenheck R, Tessler R . Factors predicting choice of provider among homeless veterans with mental illness. Psychiatr Serv. 2000; 51(8):1024-8. DOI: 10.1176/appi.ps.51.8.1024. View

2.
Darke S, Duflou J, Torok M . The comparative toxicology and major organ pathology of fatal methadone and heroin toxicity cases. Drug Alcohol Depend. 2009; 106(1):1-6. DOI: 10.1016/j.drugalcdep.2009.07.014. View

3.
Darke S, Kaye S, Duflou J . Systemic disease among cases of fatal opioid toxicity. Addiction. 2006; 101(9):1299-305. DOI: 10.1111/j.1360-0443.2006.01495.x. View

4.
Jones C, Campopiano M, Baldwin G, McCance-Katz E . National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. Am J Public Health. 2015; 105(8):e55-63. PMC: 4504312. DOI: 10.2105/AJPH.2015.302664. View

5.
Barnett P . Comparison of costs and utilization among buprenorphine and methadone patients. Addiction. 2009; 104(6):982-92. DOI: 10.1111/j.1360-0443.2009.02539.x. View